tetano
Editor, Senior Moderator
ESC Heart Fail
. 2021 Sep 17.
doi: 10.1002/ehf2.13549. Online ahead of print.
Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry
Mateusz Sokolski[SUP] 1 2 [/SUP], Sander Trenson[SUP] 2 3 [/SUP], Justyna M Sokolska[SUP] 1 2 [/SUP], Domenico D'Amario[SUP] 4 [/SUP], Philippe Meyer[SUP] 5 [/SUP], Nana K Poku[SUP] 5 [/SUP], Tor Biering-Sørensen[SUP] 6 [/SUP], Mats C Højbjerg Lassen[SUP] 6 [/SUP], Kristoffer G Skaarup[SUP] 6 [/SUP], Eduardo Barge-Caballero[SUP] 7 8 9 [/SUP], Anne-Catherine Pouleur[SUP] 10 [/SUP], Davide Stolfo[SUP] 11 [/SUP], Gianfranco Sinagra[SUP] 11 [/SUP], Klemens Ablasser[SUP] 12 [/SUP], Viktoria Muster[SUP] 13 [/SUP], Peter P Rainer[SUP] 12 [/SUP], Markus Wallner[SUP] 12 14 15 [/SUP], Alessandra Chiodini[SUP] 2 [/SUP], Pascal S Heiniger[SUP] 2 [/SUP], Fran Mikulicic[SUP] 2 [/SUP], Judith Schwaiger[SUP] 2 [/SUP], Stephan Winnik[SUP] 2 [/SUP], Huseyin A Cakmak[SUP] 16 [/SUP], Margherita Gaudenzi[SUP] 17 18 [/SUP], Massimo Mapelli[SUP] 17 18 [/SUP], Irene Mattavelli[SUP] 17 [/SUP], Matthias Paul[SUP] 19 [/SUP], Irina Cabac-Pogorevici[SUP] 20 [/SUP], Claire Bouleti[SUP] 21 [/SUP], Marzia Lilliu[SUP] 22 [/SUP], Chiara Minoia[SUP] 23 [/SUP], Jeroen Dauw[SUP] 24 25 [/SUP], Jérôme Costa[SUP] 26 [/SUP], Ahmet Celik[SUP] 27 [/SUP], Nathan Mewton[SUP] 28 29 30 [/SUP], Carlos E L Montenegro[SUP] 31 [/SUP], Yuya Matsue[SUP] 32 33 [/SUP], Goran Loncar[SUP] 34 35 [/SUP], Michal Marchel[SUP] 36 [/SUP], Aris Bechlioulis[SUP] 37 [/SUP], Lampros Michalis[SUP] 37 [/SUP], Marcus Dörr[SUP] 38 39 [/SUP], Edgard Prihadi[SUP] 40 [/SUP], Felix Schoenrath[SUP] 41 42 [/SUP], Daniel R Messroghli[SUP] 42 43 44 [/SUP], Wilfried Mullens[SUP] 24 45 [/SUP], Lars H Lund[SUP] 46 [/SUP], Giuseppe M C Rosano[SUP] 47 [/SUP], Piotr Ponikowski[SUP] 1 [/SUP], Frank Ruschitzka[SUP] 2 [/SUP], Andreas J Flammer[SUP] 2 [/SUP]
Affiliations
Abstract
Aims: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations.
Methods and results: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62-81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44-2.59], P < 0.001). After adjusting, HF remained associated with in-hospital mortality (OR 1.45 [95% confidence interval: 1.01-2.06], P = 0.041). Importantly, 186 of 1282 [15%] patients had an acute HF event during hospitalization (76 [40%] with de novo HF), which was associated with higher in-hospital mortality (89 [48%] vs. 220 [23%]) than in patients without HF event (OR 3.10 [2.24-4.29], P < 0.001).
Conclusions: Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF or acute HF de novo are common and associated with a further increase in in-hospital mortality.
Keywords: COVID-19; Cardiovascular disease; Heart failure; Risk factors; SARS-CoV2.
. 2021 Sep 17.
doi: 10.1002/ehf2.13549. Online ahead of print.
Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry
Mateusz Sokolski[SUP] 1 2 [/SUP], Sander Trenson[SUP] 2 3 [/SUP], Justyna M Sokolska[SUP] 1 2 [/SUP], Domenico D'Amario[SUP] 4 [/SUP], Philippe Meyer[SUP] 5 [/SUP], Nana K Poku[SUP] 5 [/SUP], Tor Biering-Sørensen[SUP] 6 [/SUP], Mats C Højbjerg Lassen[SUP] 6 [/SUP], Kristoffer G Skaarup[SUP] 6 [/SUP], Eduardo Barge-Caballero[SUP] 7 8 9 [/SUP], Anne-Catherine Pouleur[SUP] 10 [/SUP], Davide Stolfo[SUP] 11 [/SUP], Gianfranco Sinagra[SUP] 11 [/SUP], Klemens Ablasser[SUP] 12 [/SUP], Viktoria Muster[SUP] 13 [/SUP], Peter P Rainer[SUP] 12 [/SUP], Markus Wallner[SUP] 12 14 15 [/SUP], Alessandra Chiodini[SUP] 2 [/SUP], Pascal S Heiniger[SUP] 2 [/SUP], Fran Mikulicic[SUP] 2 [/SUP], Judith Schwaiger[SUP] 2 [/SUP], Stephan Winnik[SUP] 2 [/SUP], Huseyin A Cakmak[SUP] 16 [/SUP], Margherita Gaudenzi[SUP] 17 18 [/SUP], Massimo Mapelli[SUP] 17 18 [/SUP], Irene Mattavelli[SUP] 17 [/SUP], Matthias Paul[SUP] 19 [/SUP], Irina Cabac-Pogorevici[SUP] 20 [/SUP], Claire Bouleti[SUP] 21 [/SUP], Marzia Lilliu[SUP] 22 [/SUP], Chiara Minoia[SUP] 23 [/SUP], Jeroen Dauw[SUP] 24 25 [/SUP], Jérôme Costa[SUP] 26 [/SUP], Ahmet Celik[SUP] 27 [/SUP], Nathan Mewton[SUP] 28 29 30 [/SUP], Carlos E L Montenegro[SUP] 31 [/SUP], Yuya Matsue[SUP] 32 33 [/SUP], Goran Loncar[SUP] 34 35 [/SUP], Michal Marchel[SUP] 36 [/SUP], Aris Bechlioulis[SUP] 37 [/SUP], Lampros Michalis[SUP] 37 [/SUP], Marcus Dörr[SUP] 38 39 [/SUP], Edgard Prihadi[SUP] 40 [/SUP], Felix Schoenrath[SUP] 41 42 [/SUP], Daniel R Messroghli[SUP] 42 43 44 [/SUP], Wilfried Mullens[SUP] 24 45 [/SUP], Lars H Lund[SUP] 46 [/SUP], Giuseppe M C Rosano[SUP] 47 [/SUP], Piotr Ponikowski[SUP] 1 [/SUP], Frank Ruschitzka[SUP] 2 [/SUP], Andreas J Flammer[SUP] 2 [/SUP]
Affiliations
- PMID: 34533287
- DOI: 10.1002/ehf2.13549
Abstract
Aims: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations.
Methods and results: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62-81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44-2.59], P < 0.001). After adjusting, HF remained associated with in-hospital mortality (OR 1.45 [95% confidence interval: 1.01-2.06], P = 0.041). Importantly, 186 of 1282 [15%] patients had an acute HF event during hospitalization (76 [40%] with de novo HF), which was associated with higher in-hospital mortality (89 [48%] vs. 220 [23%]) than in patients without HF event (OR 3.10 [2.24-4.29], P < 0.001).
Conclusions: Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF or acute HF de novo are common and associated with a further increase in in-hospital mortality.
Keywords: COVID-19; Cardiovascular disease; Heart failure; Risk factors; SARS-CoV2.